ArticleMolecules (Basel, Switzerland)2018
Anti-Inflammatory Effects of Fargesin on Chemically Induced Inflammatory Bowel Disease in Mice.
Article in Molecules (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 55 citations in OpenAlex.
- Immune protection mediated by Echinococcus granulosus EgM123 in the dextran sodium Sulfate-induced colitis model in mice.Molecular biology reports · 2026Article
- Article
- Therapeutic role of melatonin on acrylamide-induced neurotoxicity via reducing ER stress, inflammation, and apoptosis in a rat model.BMC pharmacology & toxicology · 2025Article
- Pharmacological Potential and Molecular Targets of Tetrahydrofurofuranoid Lignans FromDrug design, development and therapy · 2025Review
- Bioassay-guided isolation of sesamin and fargesin from the hydroalcoholic stem extract ofFrontiers in pharmacology · 2025Article
- Exploring the potential of Fargesin fromFuture science OA · 2024Article
- Antioxidant Therapy in Inflammatory Bowel Diseases: How Far Have We Come and How Close Are We?Antioxidants (Basel, Switzerland) · 2024Review
- Notoginsenoside R1 promotes Lgr5Acta pharmacologica Sinica · 2024Article
- Pharmacological activities ofHeliyon · 2024Review
- Emerging Roles of Macrophage Polarization in Osteoarthritis: Mechanisms and Therapeutic Strategies.Orthopaedic surgery · 2024Review
- Comparative metabolism of aschantin in human and animal hepatocytes.Archives of pharmacal research · 2024Article
- Comparative metabolism of fargesin in human, dog, monkey, mouse, and rat hepatocytes.Toxicological research · 2024Article
- Biological Potential and Therapeutic Effectiveness of Phytoproduct 'Fargesin' in Medicine: Focus on the Potential of an Active Phytochemical ofRecent advances in inflammation & allergy drug discovery · 2024Review
- Lignans as Pharmacological Agents in Disorders Related to Oxidative Stress and Inflammation: Chemical Synthesis Approaches and Biological Activities.International journal of molecular sciences · 2022Review
- Protection against ulcerative colitis and colorectal cancer by evodiamine via anti‑inflammatory effects.Molecular medicine reports · 2022Article
- Comparative Lipidomic and Metabolomic Analyses Reveal the Mystery of Lacquer Oil fromFrontiers in pharmacology · 2022Article
- Article
- Fargesin ameliorates osteoarthritis via macrophage reprogramming by downregulating MAPK and NF-κB pathways.Arthritis research & therapy · 2021Article
- The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2021Article
- Lipidomics-Based Comparison of Molecular Compositions of Green, Yellow, and Red Bell Peppers.Metabolites · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fargesin is a bioactive lignan from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.